AstraZeneca wins FDA nod to remove boxed warning from asthma drug label

After reviewing results from trials involving more than 41,000 asthma patients, the FDA has agreed to remove the boxed warning of serious asthma-related outcomes for AstraZeneca‘s (NYSE:AZN) Symbicort product.

Patients using Symbicort, which combines an inhaled corticosteroid and a long-acting beta2-adrenergic agonist in a single inhaler, did not experience a significant increase in the risk of a serious asthma-related event, according to data from four clinical trials.

Get the full story at our sister site, Drug Delivery Business News.

The post AstraZeneca wins FDA nod to remove boxed warning from asthma drug label appeared first on MassDevice.

from MassDevice http://ift.tt/2BLq6zi